Literature DB >> 3392746

Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin.

S M Grunberg1, E Ehler, J E McDermed, W L Akerley.   

Abstract

Late nausea and vomiting lasting 2-7 days occurs in 20%-68% of patients receiving cisplatin. We therefore studied the effects of oral metoclopramide given at doses of 20, 50, or 100 mg four times a day for 25 doses (7 days) beginning after cisplatin to determine the maximum tolerated dose (MTD) for prophylactic oral antiemetic regimens. Patients were stratified into younger (less than or equal to 30 yr old) and older (greater than 30 yr old) groups. Dose escalation was performed without or with concomitant oral diphenhydramine. For the younger group, the MTD for metoclopramide without diphenhydramine was less than 20 mg, and the MTD with diphenhydramine was 20 mg. For the older group, the MTD without diphenhydramine was 20 mg, and the MTD with diphenhydramine was 50 mg. Extrapyramidal reactions in the younger group and agitated depression in the older group were the major dose-terminating toxic effects. Patient acceptance of these regimens was excellent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3392746     DOI: 10.1093/jnci/80.11.864

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  5 in total

1.  Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy.

Authors:  S C Grant; M G Kris; R J Gralla; R A Clark; L B Tyson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 2.  [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].

Authors:  A Du Bois
Journal:  Med Klin (Munich)       Date:  1998-01

Review 3.  Controlling cancer chemotherapy-induced emesis. An update.

Authors:  C Seynaeve; P H De Mulder; J Verweij; R J Gralla
Journal:  Pharm Weekbl Sci       Date:  1991-10-18

Review 4.  Delayed emesis following anticancer chemotherapy.

Authors:  M G Kris; K M Pisters; L Hinkley
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

Review 5.  Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis.

Authors:  Andrea C Tricco; Erik Blondal; Areti Angeliki Veroniki; Charlene Soobiah; Afshin Vafaei; John Ivory; Lisa Strifler; Roberta Cardoso; Emily Reynen; Vera Nincic; Huda Ashoor; Joanne Ho; Carmen Ng; Christy Johnson; Erin Lillie; Jesmin Antony; Derek J Roberts; Brenda R Hemmelgarn; Sharon E Straus
Journal:  BMC Med       Date:  2016-12-23       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.